Small‐molecule EGFR inhibitors (e.g., gefitinib, erlotinib, and afatinib) have been approved for lung cancer treatment as a first‐line therapy in those cases where EGFR mutations have been confirmed (Cohen et al., 2005; Hirsch et al., 2013; Thatcher et al., 2005). This evidence concerns the gene EGFR and lung carcinoma.